You are viewing: Asia Pacific Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The Asia Pacific Leukapheresis Market was valued at $24.02 Million in 2026 and projected to reach to $38.39 Million by 2031, representing a compound annual growth rate of 9.8%. The Asia Pacific leukapheresis market is positioned for substantial growth through 2031, driven by accelerating adoption of cell-based therapies and improving healthcare accessibility across the region.

Asia Pacific Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Asia Pacific Leukapheresis Market Trends and Insights

  • Asia Pacific's leukapheresis sector is driven by rising adoption of cell therapy technologies, increasing prevalence of hematologic malignancies, and expanding healthcare infrastructure across emerging economies.
  • The region's growth trajectory outpaces global averages, reflecting strong demand for advanced apheresis systems in countries with rapidly developing oncology and immunotherapy programs. Asia Pacific leukapheresis market growth is supported by growing investment in CAR-T cell therapies and other cellular immunotherapies requiring efficient cell collection and processing.
  • Asia Pacific healthcare providers are increasingly recognizing leukapheresis as a critical component of modern cancer treatment protocols.
  • The region's 9.8% compound annual growth rate underscores Asia Pacific's strategic importance in the global leukapheresis landscape, with key markets including China, Japan, South Korea, and India leading adoption and innovation..

Key Market Statistics

  • CAGR (2026-2031) 9.8% CAGR
  • Market Size, 2026 ~USD 24.02 Million
  • Forecast, 2031 ~USD 38.39 Million
  • Geography Asia Pacific

Asia Pacific Leukapheresis Market Overview

Rapid Market Expansion :

Asia Pacific leukapheresis market is projected to grow from $24.02 million in 2026 to $38.39 million by 2031, representing a 9.8% CAGR that outpaces the global average of 8.9%.

Cell Therapy Adoption Surge :

Rising adoption of advanced cell therapy technologies across Asia Pacific is driving demand for leukapheresis procedures, particularly in CAR-T cell and immunotherapy applications.

Hematologic Malignancy Prevalence :

Increasing incidence of blood cancers and hematologic malignancies in emerging Asian economies is creating sustained demand for leukapheresis as a critical therapeutic intervention.

Healthcare Infrastructure Growth :

Expanding healthcare infrastructure and investment in medical technology across emerging economies in Asia Pacific are enabling wider accessibility to leukapheresis services and equipment.

Asia Pacific Leukapheresis Market Dynamics

  • Key markets including China and Japan are investing heavily in oncology infrastructure, while emerging economies are rapidly expanding their therapeutic capabilities.
  • The region's younger population demographics and rising cancer incidence rates create sustained demand for leukapheresis procedures. Government initiatives supporting healthcare modernization and increased pharmaceutical R&D investments are further catalyzing market expansion.
  • Strategic partnerships between regional healthcare providers and global cell therapy manufacturers are enhancing service availability.
  • As reimbursement frameworks mature and clinical evidence strengthens, Asia Pacific is expected to capture an increasingly significant share of global leukapheresis demand..

Related Ecosystem

Key Takeaways

  • Asia Pacific leukapheresis market is valued at $24.02 million in 2026 and expected to grow to $38.39 million by 2031, representing a 9.8% CAGR.
  • Asia Pacific's growth rate exceeds global averages, driven by expanding cell therapy adoption and rising hematologic malignancy incidence across the region.
  • Asia Pacific markets are increasingly investing in CAR-T and advanced immunotherapy infrastructure, positioning leukapheresis as essential to treatment protocols.
  • Asia Pacific's emerging economies, particularly China, Japan, South Korea, and India, are key growth drivers for leukapheresis technology adoption and market expansion.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

Asia Pacific Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

Target Audience

  • Medical Device Manufacturers : Manufacturers need Asia Pacific market data to expand leukapheresis equipment portfolios, identify distribution partnerships, and capitalize on growing demand for apheresis systems in the region.
  • Pharmaceutical Companies : Pharma firms developing cell therapies require regional market insights to understand leukapheresis service availability, pricing models, and clinical adoption rates for commercialization planning.
  • Healthcare Providers & Hospitals : Hospital networks and treatment centers need market intelligence to justify capital investments in leukapheresis infrastructure and assess competitive positioning within Asia Pacific markets.
  • Investment & Private Equity Firms : Investors evaluating healthcare opportunities in Asia Pacific require detailed market sizing, growth projections, and regional dynamics to assess portfolio companies and acquisition targets.
  • Healthcare Consultants & Analysts : Consulting firms and research analysts need comprehensive Asia Pacific data to support client strategy development, market assessments, and competitive intelligence across the leukapheresis sector.

Key Companies in the Asia Pacific Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Asia Pacific vs. other regions

HowAsia Pacific compares to the other 3 regional blocs covered in this market.

North America
~USD 55.55 Million · 9.3% wtd CAGR ·
Europe
~USD 38.06 Million · 8% wtd CAGR ·
Latin America
~USD 4.75 Million · 6.6% wtd CAGR ·

Countries within Asia Pacific - compare and drill down

Country2025 size (native)
ChinaUSD 9.17 Million
JapanUSD 9.04 Million
IndiaUSD 1.59 Million
AustraliaUSD 2.74 Million
South KoreaUSD 3.22 Million
New ZealandUSD 0.91 Million
ThailandUSD 0.7 Million
Rest Of Asia PacificUSD 2.56 Million

Country market size visualization

China
USD 9.17 Million
Japan
USD 9.04 Million
India
USD 1.59 Million
Australia
USD 2.74 Million
South Korea
USD 3.22 Million
New Zealand
USD 0.91 Million
Thailand
USD 0.7 Million
Rest Of Asia Pacific
USD 2.56 Million

Reasons to Buy this Report

  • Regional Growth Opportunity : Capture insights into the fastest-growing leukapheresis market segment with 9.8% CAGR, outpacing global growth and offering superior investment returns in Asia Pacific.
  • Market Entry Strategy : Develop targeted market entry strategies for emerging economies with detailed analysis of healthcare infrastructure expansion, regulatory environments, and competitive landscapes across Asia Pacific.
  • Country-Level Intelligence : Access granular market data for key Asia Pacific countries including China, Japan, South Korea, India, and Australia to identify high-potential markets and localize business strategies.
  • Technology Adoption Trends : Understand cell therapy adoption patterns and leukapheresis procedure demand drivers specific to Asia Pacific, enabling product development and commercialization aligned with regional needs.
  • Competitive Positioning : Benchmark your organization against regional competitors and identify white-space opportunities in emerging markets where leukapheresis infrastructure and services remain underdeveloped.

Frequently asked questions

What is the current market size of leukapheresis in Asia Pacific?

The Asia Pacific leukapheresis market is valued at $24.02 million in 2026 and is projected to reach $38.39 million by 2031.

What is the growth rate of the Asia Pacific leukapheresis market?

Asia Pacific leukapheresis market is growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2031.

Which countries are driving growth in Asia Pacific leukapheresis market?

Key markets in Asia Pacific include China, Japan, South Korea, and India, which are leading adoption of leukapheresis technologies and cellular immunotherapies.

What factors are driving leukapheresis demand in Asia Pacific?

Asia Pacific leukapheresis demand is driven by rising CAR-T cell therapy adoption, increasing hematologic malignancy prevalence, and expanding healthcare infrastructure in emerging economies.

How does Asia Pacific leukapheresis growth compare to global trends?

Asia Pacific's 9.8% CAGR exceeds the global average of 8.9%, reflecting the region's accelerating adoption of advanced cell therapy and immunotherapy technologies.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status